ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 927,57
-0,72%
Dow Jones
37 978,77
0,20%
DAX
17 909,87
-0,07%
Brent Oil
83,515
-0,03%
Bitcoin
58 488,70
0,43%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sutro Biopharma Inc (STRO)

  7. Sutro Biopharma Inc (STRO) Actualités

STRO Sutro Biopharma Inc

3,77
0,03 (0,80%)
Dernière mise à jour : 16:03:01
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Sutro Biopharma Inc STRO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,03 0,80% 3,77 16:03:01
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,80 3,695 3,99 3,74
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202414:00GLOBESutro Biopharma Announces Initiation of Randomized Portion..
02/4/202412:18GLOBESutro Biopharma Announces Pricing of $75 Million..
25/3/202421:30GLOBESutro Biopharma Reports Full Year 2023 Financial Results,..
07/3/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202422:33EDGAR2Form S-8 - Securities to be offered to employees in employee..
13/2/202418:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202412:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202422:27EDGAR2Form 8-K - Current report
09/2/202422:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/2/202422:05GLOBESutro Biopharma to Participate in Upcoming Investor..
31/1/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202423:14EDGAR2Form 144 - Report of proposed sale of securities
08/1/202413:31EDGAR2Form 8-K - Current report
04/1/202422:05GLOBESutro Biopharma Highlights Potential Multi-Cancer..
14/12/202322:05GLOBESutro Biopharma to Host Investor Webcast Highlighting..
11/12/202322:05GLOBESutro Biopharma Announces New Positive Data from the..
04/12/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202322:05GLOBESutro Biopharma to Participate in the JMP Securities..
27/11/202322:05EDGAR2Form 8-K - Current report
27/11/202322:00GLOBEVaxcyte Exercises Option and Enters into Manufacturing..
22/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
21/11/202322:05EDGAR2Form 8-K - Current report
21/11/202322:05GLOBESutro Biopharma Promotes Jane Chung to President and Chief..
13/11/202323:18EDGAR2Form S-3 - Registration statement under Securities Act of..
13/11/202322:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:30EDGAR2Form 8-K - Current report
13/11/202322:30GLOBESutro Biopharma Reports Third Quarter 2023 Financial..
22/10/202310:25GLOBESutro Biopharma Announces Presentation of Data for..
16/10/202322:05GLOBESutro Demonstrates Meaningful ADC Innovation with Five..
04/10/202322:31EDGAR2Form 8-K - Current report
19/9/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/9/202322:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/9/202314:00GLOBESutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief..
30/8/202314:00GLOBESutro Biopharma to Participate in Upcoming Investor..
29/8/202322:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202322:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202322:46EDGAR2Form 144 - Report of proposed sale of securities
11/8/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202322:31EDGAR2Form 8-K - Current report
10/8/202322:30GLOBESutro Biopharma Reports Second Quarter 2023 Financial..
14/7/202300:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/6/202314:00GLOBESutro Biopharma and Blackstone Announce Royalty Financing..
03/6/202322:00GLOBESutro Biopharma Announces Oral Presentation at ASCO 2023..
31/5/202314:00GLOBESutro Biopharma to Participate in the Jefferies Healthcare..

Dernières Valeurs Consultées

NASDAQ
STRO
Sutro Biopharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés